NASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis $3.91 +0.03 (+0.77%) Closing price 04:00 PM EasternExtended Trading$3.90 -0.01 (-0.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Prelude Therapeutics Stock (NASDAQ:PRLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prelude Therapeutics alerts:Sign Up Key Stats Today's Range$3.72▼$3.9850-Day Range$3.83▼$6.6352-Week Range$1.15▼$6.83Volume496,150 shsAverage Volume479,491 shsMarket Capitalization$312.02 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target biological mechanisms that cancer cells depend on, including epigenetic regulators and other proteins involved in tumor growth and survival. Prelude’s development programs have included PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor; PRT3789, a SMARCA2 protein degrader; and PRT1419, an inhibitor of the MCL1 protein. These candidates have been investigated for potential use in treating cancers with specific molecular characteristics, including hematologic malignancies and solid tumors. Founded in 2016 and headquartered in Wilmington, Delaware, Prelude has advanced its programs through preclinical research and clinical development in the United States. As a biotechnology company, its activities are primarily focused on research, drug development, and the evaluation of investigational therapies rather than commercial product sales.AI Generated. May Contain Errors. Read More Prelude Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScorePRLD MarketRank™: Prelude Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 666th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingPrelude Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPrelude Therapeutics has a consensus price target of $8.75, representing about 123.8% upside from its current price of $3.91.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Prelude Therapeutics are expected to decrease in the coming year, from ($0.61) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.95% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Prelude Therapeutics has recently increased by 0.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentPrelude Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for PRLD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Prelude Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders49.20% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRLD Stock News HeadlinesPrelude Therapeutics (NASDAQ:PRLD) Coverage Initiated at JPMorgan Chase & Co.September 19, 2026 | americanbankingnews.comPrelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 11, 2026 | globenewswire.comShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.September 28 at 1:00 AM | SmartAsset (Ad)Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...September 10, 2026 | finanznachrichten.dePrelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast CancerSeptember 10, 2026 | rttnews.comPrelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug TrialSeptember 10, 2026 | finance.yahoo.comPrelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective DegraderSeptember 10, 2026 | globenewswire.comPrelude Therapeutics: A Prognosis After Year-Long RallyAugust 23, 2026 | seekingalpha.comSee More Headlines PRLD Stock Analysis - Frequently Asked Questions How have PRLD shares performed this year? Prelude Therapeutics' stock was trading at $2.90 on January 1st, 2026. Since then, PRLD shares have increased by 34.8% and is now trading at $3.91. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its earnings results on Tuesday, August, 11th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. The business earned $5.70 million during the quarter, compared to the consensus estimate of $5.70 million. When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $150 million in an IPO on Friday, September 25th 2020. The company issued 8,325,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Prelude Therapeutics' top institutional investors include BlackRock Inc. (2.26%), ADAR1 Capital Management LLC (1.13%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Bank of New York Mellon Corp (0.09%). Insiders that own company stock include David P Bonita, Orbimed Advisors Llc, Krishna Vaddi, Krishna Vaddi, Andrew Combs and Bryant David Lim. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prelude Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today9/28/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRLD's financial health is in the Green zone, according to TradeSmith. PRLD has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRLD CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees79Year Founded2016Price Target and Rating Average Price Target for Prelude Therapeutics$8.75 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+123.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$99.50 million Net MarginsN/A Pretax Margin-338.98% Return on Equity-75.35% Return on Assets-44.39% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$12.14 million Price / Sales25.70 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book3.59Miscellaneous Outstanding Shares79,800,000Free Float40,540,000Market Cap$312.02 million OptionableOptionable Beta0.97 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:PRLD) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
